JP6445565B2 - とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 - Google Patents

とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 Download PDF

Info

Publication number: JP6445565B2
Authority: JP; Japan
Prior art keywords: chloro; compound; propyl; sulfamoyl; formula
Prior art date: 2013-09-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2016540921A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016532716A5 (2

JP2016532716A (ja

Inventor

オルガバビチ

ティナギャリアンテス

ロバートズィー．ルオ

デイヴィッドジェイ．パリング

スリニヴァサンピー．ヴェンカタチャラン

ヤンリンワン−フィッシャー

Original Assignee

クロモセルコーポレイション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-10

Filing date

2014-09-09

Publication date

2018-12-26

2014-09-09 Application filed by クロモセルコーポレイション, クロモセルコーポレイション filed Critical クロモセルコーポレイション

2016-10-20 Publication of JP2016532716A publication Critical patent/JP2016532716A/ja

2017-10-19 Publication of JP2016532716A5 publication Critical patent/JP2016532716A5/ja

2018-12-26 Application granted granted Critical

2018-12-26 Publication of JP6445565B2 publication Critical patent/JP6445565B2/ja

Status Active legal-status Critical Current

2034-09-09 Anticipated expiration legal-status Critical

Links

0 *CCCc(cccc1)c1NC(C#S(C1)=I)=C=C/C=C1/[N+](**)[O-] Chemical compound *CCCc(cccc1)c1NC(C#S(C1)=I)=C=C/C=C1/[N+](**)[O-] 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Thiazole And Isothizaole Compounds (AREA)

JP2016540921A 2013-09-10 2014-09-09 とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 Active JP6445565B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361876046P	2013-09-10	2013-09-10
US61/876,046		2013-09-10
PCT/US2014/054764 WO2015038533A2 (en)	2013-09-10	2014-09-09	Sodium channel modulators for the treatment of pain and diabetes

Publications (3)

Publication Number	Publication Date
JP2016532716A JP2016532716A (ja)	2016-10-20
JP2016532716A5 JP2016532716A5 (2)	2017-10-19
JP6445565B2 true JP6445565B2 (ja)	2018-12-26

Family

ID=52666496

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016540921A Active JP6445565B2 (ja)	2013-09-10	2014-09-09	とう痛及び糖尿病の治療用ナトリウムチャネル調節物質

Country Status (18)

Country	Link
US (2)	US20160221974A1 (2)
EP (1)	EP3043787B1 (2)
JP (1)	JP6445565B2 (2)
KR (1)	KR20160054570A (2)
CN (1)	CN105611923B (2)
AU (1)	AU2014318979B2 (2)
BR (1)	BR112016005271A2 (2)
CA (1)	CA2922851C (2)
ES (1)	ES2687598T3 (2)
IL (1)	IL244506B (2)
MX (1)	MX2016002881A (2)
MY (1)	MY181928A (2)
PH (1)	PH12016500296A1 (2)
RU (1)	RU2016113156A (2)
SG (2)	SG10201805552PA (2)
UA (1)	UA120353C2 (2)
WO (1)	WO2015038533A2 (2)
ZA (1)	ZA201702410B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2687481T3 (es) *	2013-03-15	2018-10-25	Chromocell Corporation	Moduladores del canal de sodio para el tratamiento del dolor
AU2014318979B2 (en)	2013-09-10	2019-03-28	Chromocell Corporation	Sodium channel modulators for the treatment of pain and diabetes
EP3193610A4 (en) *	2014-09-09	2018-04-04	Chromocell Corporation	Selective nav1.7 inhibitors for the treatment of diabetes
EP3390374B1 (en)	2015-12-18	2020-08-26	Merck Sharp & Dohme Corp.	Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
HRP20250505T1 (hr)	2016-05-20	2025-06-20	Xenon Pharmaceuticals Inc.	Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
CN106084535A (zh) *	2016-06-02	2016-11-09	扬州兰都塑料科技有限公司	一种耐刮擦的电力电缆的制备方法
CN105924670A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种电力电缆用耐磨剂
CN105924843A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种耐刮擦的电力电缆
ES2967410T3 (es)	2016-12-09	2024-04-30	Xenon Pharmaceuticals Inc	Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN106892845B (zh) *	2017-02-28	2018-10-30	四川同晟生物医药有限公司	一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) *	2018-04-13	2019-10-17	Chromocell Corporation	Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) *	2018-05-11	2019-11-14	Chromocell Corporation	Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
CN112262142B (zh)	2018-06-13	2023-11-14	泽农医药公司	苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es)	2018-08-31	2021-05-27	Xenon Pharmaceuticals Inc	Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr)	2018-08-31	2021-12-08	Xenon Pharmaceuticals Inc	Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN113527281B (zh) *	2020-04-20	2023-12-22	昆山彭济凯丰生物科技有限公司	杂环化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5356897A (en)	1991-09-09	1994-10-18	Fujisawa Pharmaceutical Co., Ltd.	3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DE50207103D1 (en) *	2001-03-14	2006-07-20	Gruenenthal Gmbh	Substituierte pyrazolo- und thiazolopyrimidine als analgetika
US7659082B2 (en)	2002-02-19	2010-02-09	Xenon Pharmaceuticals Inc.	Methods for identifying analgesic agents
AU2003243921B2 (en)	2002-06-27	2009-05-07	Novo Nordisk A/S	Aryl carbonyl derivatives as therapeutic agents
GB0324792D0 (en)	2003-10-23	2003-11-26	Sterix Ltd	Compound
US7449477B2 (en)	2003-11-25	2008-11-11	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
CA2564355C (en)	2004-05-07	2012-07-03	Amgen Inc.	Protein kinase modulators and method of use
AU2005266090A1 (en) *	2004-07-23	2006-02-02	Pfizer Inc.	Pyridine derivatives
US20090093485A1 (en)	2004-10-29	2009-04-09	Astrazeneca Ab	Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
UA96283C2 (uk) *	2005-12-23	2011-10-25	Зіланд Фарма А/С	Модифіковані міметики лізину
AU2008213836A1 (en) *	2007-02-05	2008-08-14	Xenon Pharmaceuticals Inc.	Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
US8124610B2 (en)	2007-07-13	2012-02-28	Icagen Inc.	Sodium channel inhibitors
WO2009012241A1 (en)	2007-07-13	2009-01-22	Icagen, Inc.	Sodium channel inhibitors
PE20120008A1 (es) *	2009-01-12	2012-01-24	Icagen Inc	Derivados de fenoxi bencenosulfonamida
CN105254557A (zh)	2009-05-29	2016-01-20	拉夸里亚创药株式会社	作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
JP2013525368A (ja)	2010-04-23	2013-06-20	キネタ・インコーポレイテツド	抗ウイルス性化合物
ES2526675T3 (es)	2010-07-09	2015-01-14	Pfizer Limited	N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
CA2804593C (en) *	2010-07-09	2015-11-24	Pfizer Limited	Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP5872552B2 (ja)	2010-07-09	2016-03-01	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	化学化合物
JP2013536165A (ja)	2010-07-12	2013-09-19	ファイザー・リミテッド	痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2014507136A (ja)	2011-01-18	2014-03-27	アムジエン・インコーポレーテツド	ＮａＶ１．７ノックアウトマウスとそれらの使用
UY34171A (es) *	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
MX2014001851A (es)	2011-08-17	2014-10-24	Amgen Inc	Inhibidores del canal de heteroarilo sodio.
WO2013043925A1 (en) *	2011-09-21	2013-03-28	Gilead Sciences, Inc.	Sodium channel blockers reduce glucagon secretion
JP6014155B2 (ja)	2011-10-31	2016-10-25	ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
CA2890897A1 (en)	2012-11-14	2014-05-22	The Board Of Regents Of The University Of Texas System	Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
ES2687481T3 (es) *	2013-03-15	2018-10-25	Chromocell Corporation	Moduladores del canal de sodio para el tratamiento del dolor
PL3417851T3 (pl)	2013-09-09	2020-12-14	Peloton Therapeutics, Inc.	Etery arylowe i ich zastosowanie
AU2014318979B2 (en)	2013-09-10	2019-03-28	Chromocell Corporation	Sodium channel modulators for the treatment of pain and diabetes
EP3193610A4 (en)	2014-09-09	2018-04-04	Chromocell Corporation	Selective nav1.7 inhibitors for the treatment of diabetes

2014
- 2014-09-09 AU AU2014318979A patent/AU2014318979B2/en not_active Ceased
- 2014-09-09 US US15/021,153 patent/US20160221974A1/en not_active Abandoned
- 2014-09-09 EP EP14843353.5A patent/EP3043787B1/en active Active
- 2014-09-09 MY MYPI2016700824A patent/MY181928A/en unknown
- 2014-09-09 SG SG10201805552PA patent/SG10201805552PA/en unknown
- 2014-09-09 WO PCT/US2014/054764 patent/WO2015038533A2/en not_active Ceased
- 2014-09-09 ES ES14843353.5T patent/ES2687598T3/es active Active
- 2014-09-09 RU RU2016113156A patent/RU2016113156A/ru not_active Application Discontinuation
- 2014-09-09 BR BR112016005271-4A patent/BR112016005271A2/pt not_active IP Right Cessation
- 2014-09-09 CN CN201480049690.8A patent/CN105611923B/zh not_active Expired - Fee Related
- 2014-09-09 SG SG11201601367QA patent/SG11201601367QA/en unknown
- 2014-09-09 MX MX2016002881A patent/MX2016002881A/es active IP Right Grant
- 2014-09-09 CA CA2922851A patent/CA2922851C/en active Active
- 2014-09-09 UA UAA201603676A patent/UA120353C2/uk unknown
- 2014-09-09 KR KR1020167009294A patent/KR20160054570A/ko not_active Ceased
- 2014-09-09 JP JP2016540921A patent/JP6445565B2/ja active Active
2016
- 2016-01-13 US US14/994,846 patent/US9458118B2/en active Active
- 2016-02-12 PH PH12016500296A patent/PH12016500296A1/en unknown
- 2016-03-09 IL IL244506A patent/IL244506B/en active IP Right Grant
2017
- 2017-04-05 ZA ZA2017/02410A patent/ZA201702410B/en unknown

Also Published As

Publication number	Publication date
BR112016005271A2 (pt)	2020-05-12
MX2016002881A (es)	2016-04-21
US9458118B2 (en)	2016-10-04
MY181928A (en)	2021-01-14
KR20160054570A (ko)	2016-05-16
WO2015038533A2 (en)	2015-03-19
EP3043787A4 (en)	2017-02-01
ZA201702410B (en)	2019-06-26
AU2014318979A1 (en)	2016-03-03
PH12016500296A1 (en)	2016-05-16
AU2014318979B2 (en)	2019-03-28
CA2922851C (en)	2023-03-14
IL244506B (en)	2020-02-27
US20160221974A1 (en)	2016-08-04
CN105611923B (zh)	2019-08-23
SG10201805552PA (en)	2018-08-30
CA2922851A1 (en)	2015-03-19
SG11201601367QA (en)	2016-03-30
ES2687598T3 (es)	2018-10-26
EP3043787A2 (en)	2016-07-20
UA120353C2 (uk)	2019-11-25
CN105611923A (zh)	2016-05-25
WO2015038533A3 (en)	2015-10-29
IL244506A0 (en)	2016-04-21
JP2016532716A (ja)	2016-10-20
RU2016113156A3 (2)	2018-07-02
RU2016113156A (ru)	2017-10-16
EP3043787B1 (en)	2018-09-05
US20160130239A1 (en)	2016-05-12

Legal Events

Date	Code	Title	Description
2017-09-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170908
2017-09-08	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170908
2018-05-15	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180515
2018-05-21	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180517
2018-08-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180815
2018-10-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181015
2018-10-29	TRDD	Decision of grant or rejection written
2018-11-06	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106
2018-12-06	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181129
2018-12-07	R150	Certificate of patent or registration of utility model	Ref document number: 6445565 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2021-12-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-06-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-05-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-12-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-08-19	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6445565B2 (ja)	2018-12-26	とう痛及び糖尿病の治療用ナトリウムチャネル調節物質
JP6449845B2 (ja)	2019-01-09	疼痛の処置のためのナトリウムチャネルモジュレーター
JPWO2011007819A1 (ja)	2012-12-27	ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
CN102958925A (zh)	2013-03-06	吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
JP2017527573A (ja)	2017-09-21	糖尿病の治療用の選択的ＮａＶ１．７阻害剤
CN110177782A (zh)	2019-08-27	RORγ调节剂及其用途
JP6483272B2 (ja)	2019-03-13	白色脂肪組織の褐色化を誘導するための化合物および方法
TW202146381A (zh)	2021-12-16	可用作RORγ調節劑的聯芳基類化合物
CA2853485A1 (en)	2013-05-02	Compounds for inflammation and immune-related uses
CN110177775A (zh)	2019-08-27	RORγ调节剂及其用途
HK1224572A1 (en)	2017-08-25	Sodium channel modulators for the treatment of pain and diabetes
CA3163568A1 (en)	2021-07-08	Isoquinoline derivatives for use in treating glut1 deficiency syndrome
JP2019529503A (ja)	2019-10-17	置換フェニルプロピオン酸化合物のエナンチオマー及びその製造方法、、組成物並びに応用
WO2014077532A1 (ko)	2014-05-22	신규한 피페라진 유도체, 이의 약학적으로 허용가능한 염 또는 이의 광학이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학적 조성물
TW202423915A (zh)	2024-06-16	抗炎化合物、藥物組合物以及治療血色病和其它疾患的方法